Abstract: The present invention provides an NKT cell stimulating agent containing antigen-presenting cells pulsed with an NKT cell ligand, to be administered submucosally in the upper airway. By submucosal administration in the upper airway, it is possible to stimulate NKT cells and stimulate immune reactions extremely efficiently with a small number of NKT cell ligand-pulsed antigen-presenting cells. By submucosal administration in the upper airway, NKT cells can be induced selectively in cervical lymph nodes.

Abstract: A liposome containing a regulatory cell ligand such as ?-galactosyl ceramide or ?-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.

Abstract: An encoder encodes sound data and the like to generate a binary signal. A mapper converts the binary signal into a four-level symbol and outputs the four-level symbol. A base band filter includes a root raised cosine filter and a sinc filter. The base band filter blocks a predetermined frequency component of a symbol to shape the symbol into a waveform signal and outputs the waveform signal shaped. An FM modulator transmits a signal subjected to FM modulation according to a magnitude of an amplitude of a waveform signal to a receiving unit. When a symbol of ±3 is outputted from the mapper, a frequency shift of a signal transmitted from the FM modulator has a predetermined value in a range of 0.822 [kHz] to 0.952 [kHz]. This makes it possible to provide a modulating apparatus, a mobile communication system, a modulating method, and a communication method that use a modulating method that can conform to the FCC rule to be enforced in 2005 without using a linear power amplifier.

Abstract: The present invention provides a method of producing a cloned mammal, which uses a mammalian natural killer T cell as a donor cell, a cloned mammal obtained by the method, a method of obtaining an ES cell from the embryo of the cloned animal and an ES cell obtained by the method.

Abstract: The invention provides a pseudoglycolipid effective for cancer treatment and the like and a novel synthesis intermediate therefor, as well as a medicament containing the pseudoglycolipid and the like. The inventive compound is represented by the formula (1), or a salt thereof, wherein each symbol is as defined in the specification.

Abstract: An encoder encodes audio data and the like to generate a binary signal. A mapper converts the binary signal into a four-level symbol and outputs the four-level symbol. A base band filter includes a root raised cosine filter and a sinc filter. The base band filter blocks a predetermined frequency component of a symbol to shape the symbol into a waveform signal and outputs the waveform signal shape. An FM modulator transmits a signal subjected to FM modulation according to a magnitude of an amplitude of a waveform signal to a receiving unit. When a symbol of ±3 is outputted from the mapper, a frequency shift of a signal transmitted from the FM modulator has a predetermined value in a range of ±0.822 [kHz] to ±0.952 [kHz]. This makes it possible to provide a modulating apparatus, a mobile communication system, a modulating method, and a communication method that use a modulating method that can conform to the FCC rule to be enforced in 2005 without using a linear power amplifier.

Abstract: An encoder encodes sound data and the like to generate a binary signal. A mapper converts the binary signal into a quaternary symbol and outputs the quaternary symbol. A base band filter includes a root raised cosine filter and a sinc filter. The base band filter blocks a predetermined frequency component of a symbol to shape the symbol into a waveform signal and outputs the waveform signal shaped. An FM modulator transmits a signal subjected to FM modulation according to a magnitude of an amplitude of a waveform signal to a receiving unit. When a symbol of ±3 is outputted from the mapper, a frequency shift of a signal transmitted from the FM modulator has a predetermined value in a range of ±0.822 [kHz] to ±0.952 [kHz]. This makes it possible to provide a modulating apparatus, a mobile communication system, a modulating method, and a communication method that use a modulating method that can conform to the FCC rule to be enforced in 2005 without using a linear power amplifier.

Abstract: The present invention provide a compound represented by the following formula (1) wherein each symbol is as defined in the specification, or a salt thereof. The compound of the present invention and a salt thereof can preferentially induce production of IL-4, which is one kind of cytokines that control action of immunocytes. Therefore, it is useful for the prophylaxis or treatment of autoimmune diseases, infectious diseases and the like, and prophylaxis or treatment of diseases caused by functional promotion of Th1 cells.

Abstract: The present invention provides a nasal vaccine capable of intranasally inducing an effective immunity reaction. Specifically, the invention provides a nasal vaccine containing a compound having an NKT cell-activating action, particularly a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a compound represented by the formula (II): wherein each symbol is as defined in the specification, and an immunogen in an amount effective for stimulating an immune response.

Abstract: The present invention relates to a compound represented by the following formula (1?) wherein R is an aldopyranose residue, R2 is a C2-18 hydrocarbon group optionally having substituent(s), R3 is an acyl group, X is an oxygen atom, a sulfur atom or —NH—, and p is an integer of 0-4, or a salt thereof. The compound of the present invention has a specific immunoregulatory ability, and is useful for the prophylaxis or treatment of autoimmune diseases and the like.

Abstract: It is an object of the present invention to identify a membrane molecule that is specifically expressed on activated plasmacytoid dendritic cells, for the purpose of preventing or improving affection or disease such as cancer, autoimmune disease, allergy, or infectious disease by regulating the functions of dendritic cells capable of integrating an immune system. The present invention provides a protein having any one of the following amino acid sequences: (a) an amino acid sequence as shown in SEQ ID NO: 2; (b) an amino acid sequence, which comprises a deletion, substitution, insertion and/or addition of one or several amino acid residues with respect to the amino acid sequence as shown in SEQ ID NO: 2, and which is capable of regulating the functions of dendritic cells; and (c) an amino acid sequence, which has homology of 80% or more with the amino acid sequence as shown in SEQ ID NO: 2, and which is capable of regulating the functions of dendritic cells.

Abstract: The present invention provides an agent for promoting human Th1 cell differentiation and an agent for suppressing human Th2 cell differentiation, comprising lipoarabinomannans and/or lipomannans derived from BCG cell bodies. The agent of the present invention is useful as a prophylactic/therapeutic agent for cancers and the like, and also as a therapeutic agent for allergic diseases such as pollinosis.

Abstract: When no messages are existent which must be notified to a mobile transmitting/receiving apparatus (102), a carrier signal of non-modulation is outputted in an area of control information of transport data having a frame structure. As a specific example, an FSK modulator (16) causes a transmitting circuit (17) to output a carrier signal of non-modulation from a line control apparatus (101) in correspondence with the area for control information in which non-modulation data is set by a frame data processing unit (15), while causing a modulated wave signal as four-level FSK modulated to be outputted in the areas other than the non-modulation data area. When non-modulation data is set in the area for control information, function channel identification information in the same frame is set as non-modulation identification data, thereby avoiding any unstable operation in the mobile transmitting/receiving apparatus (102) at the receiving end.

Abstract: When a sound presence/absence detector (12) detects a sound absence interval, a non-modulated carrier signal is outputted in an area used to transmit speech data that are included in transmission data having a frame structure and that correspond to the sound absence interval. That is, an FSK modulator (14) causes a transmitting circuit (15) to output the non-modulated carrier signal from a wireless communication apparatus (100) in the area used to transmit the speech data corresponding to the sound absence interval. In the meantime, a four-level FSK modulated wave signal is outputted in the areas other than the one of the sound absence interval. A non-modulation discriminating data for allowing the sound absence interval to be determined are included in an area of channel identifying information included in the transmission data having the frame structure, and allow a communication terminal apparatus at the receiving end to avoid any unstable operations.

Abstract: Information, which has a frame structure and is to be transmitted from a line control apparatus (101) through a control channel to a mobile transmitting/receiving apparatus (102), includes function channel identifying information indicative of the type of information transmitted in an area of control information. When no message is existent which must be notified to the mobile transmitting/receiving apparatus (102), the line control apparatus (101) establishes an idle message in the area of control information and also establishes the function channel identifying information, which is in the same frame, as idle identifying information. If the function channel identifying information is the idle identifying information, the mobile transmitting/receiving apparatus (102) switches a receiving operation in the area of control information into a reception stop operation. Otherwise, the mobile transmitting/receiving apparatus (102) continues the receiving operation in the area of control information.

Abstract: An encoder encodes sound data and the like to generate a binary signal. A mapper converts the binary signal into a quaternary symbol and outputs the quaternary symbol. A base band filter includes a root raised cosine filter and a sinc filter. The base band filter blocks a predetermined frequency component of a symbol to shape the symbol into a waveform signal and outputs the waveform signal shaped. An FM modulator transmits a signal subjected to FM modulation according to a magnitude of an amplitude of a waveform signal to a receiving unit. When a symbol of ±3 is outputted from the mapper, a frequency shift of a signal transmitted from the FM modulator has a predetermined value in a range of ±0.822[kHz] to ±0.952[kHz]. This makes it possible to provide a modulating apparatus, a mobile communication system, a modulating method, and a communication method that use a modulating method that can conform to the FCC rule to be enforced in 2005 without using a linear power amplifier.

Abstract: A liposome containing a regulatory cell ligand such as ?-galactosyl ceramide or ?-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.

Abstract: An objective of the present invention is to provide NKT cell-activating agents, therapeutic agents for autoimmune diseases (for example, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes), and abortifacients. The medicinal compositions according to the present invention comprise &agr;-glycosylceramides of the following formula (I), or a salt or a solvate thereof as an active ingredient.

Abstract: An objective of the present invention is to provide NKT cell-activating agents, therapeutic agents for autoimmune diseases (for example, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes), and abortifacients. The medicinal compositions according to the present invention comprise &agr;-glycosylceramides of the following formula (I), or a salt or a solvate thereof as an active ingredient.

Abstract: An objective of the present invention is to provide NKT cell-activating agents, therapeutic agents for autoimmune diseases (for example, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes), and abortifacients. The medicinal compositions according to the present invention comprise &agr;-glycosylceramides of the following formula (I), or a salt or a solvate thereof as an active ingredient.